HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2820 Tregalizumab (Anti-CD4) Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD. Human IgG1
A2821 Anti-CD4 (TRX1) Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD. Human IgG1
A3077 Tilogotamab (Anti-TNFRSF10B / TRAILR2 / CD262) Tilogotamab (Anti-TNFRSF10B / TRAILR2 / CD262) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). It can be used for the research of multiple myeloma (MM). MW :144.88 KD. Human IgG1
A2822 Depemokimab (Anti-IL-5) Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD. Human IgG1
A3078 Anti-F3 / Factor III / Tissue Factor / CD142 (TNX-832) Anti-F3 / Factor III / Tissue Factor / CD142 (TNX-832) is humanized form of an antibody capable of targeting tissue factor (coagulation factor F3). It is useful in treating conditions, such as tumor progression.MW :144.34 KD. Human IgG4SP
A2823 Divozilimab (Anti-CD20) Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD. Human IgG1
A3079 Benufutamab (Anti-TNFRSF10B / TRAILR2 / CD262) Benufutamab (Anti-TNFRSF10B / TRAILR2 / CD262) is an agonistic antibody specificly targeting death receptor 5 (DR5).It has antitumor effects and can be used for the research of multiple myeloma (MM). MW :1145.12 KD. Human IgG1
A2824 Letaplimab (Anti-CD47) Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD. Human IgG4SP
A2825 Ligufalimab (Anti-CD47) Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD. Human IgG4SP
A2826 Domagrozumab (Anti-GDF8 / Myostatin) Domagrozumab (Anti-GDF8 / Myostatin) is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab has the potential to be used in research of duchenne muscular dystrophy (DMD). MW : 143.96 KD. Human IgG1
A3082 Toripalimab (Anti-PDCD1 / PD-1 / CD279) Toripalimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody targeting PD-1. It has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. 147.3 KD. Human IgG4SP
A2827 Urabrelimab (Anti-CD47) Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD. Human IgG4SP
A3083 Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD. Human IgG1
A3084 Torudokimab (Anti-IL-33) Torudokimab (Anti-IL-33) is a fully human monoclonal antibody targeting human IL-33. It can be used in research of atopic dermatitis. MW :145.22 KD. Human IgG4SP
A3085 Tozorakimab (Anti-IL-33) Tozorakimab (Anti-IL-33) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. It can be used to research chronic obstructive pulmonary disease. MW :144.54 KD. Human IgG1
A2830 Gatralimab (Anti-CD52) Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD. Human IgG1
A3086 Anti-Amyloid Beta (U.Illinois scFv59) Anti-Amyloid Beta (U.Illinois scFv59) is a single-chain antibody targeting amyloid-β (Aβ) protein. It can be used in Alzheimer's disease (AD) research. MW :142.56 KD Human IgG1
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD. Human IgG1
A3087 Lucatumumab (Anti-TNFRSF5 / CD40) Lucatumumab (Anti-TNFRSF5 / CD40) is a fully human antagonist monoclonal antibody, targeting CD40. It exhibits clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. MW :150 KD. Human IgG1
A2832 Domvanalimab (Anti-TIGIT) Domvanalimab (Anti-TIGIT) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) with potential immune checkpoint inhibitory activity. MW : 145.12 KD. Human IgG1